Lusvertikimab posts strong phase II ulcerative colitis results, advancing
Lusvertikimab, an anti-IL-7 receptor antibody, reported robust efficacy and safety in phase II ulcerative colitis trials, with consistent improvements across clinical, endoscopic and histological endpoints. Development is advancing into pouchitis trials.
Lusvertikimab, an anti-IL-7 receptor antibody, demonstrated robust efficacy and safety in phase II ulcerative colitis trials, with consistent improvements across clinical, endoscopic, and histological endpoints.
Its unique mechanism and promising biomarker-driven results support ongoing development…